Abstract Severe coronavirus disease 2019 (COVID-19) is known to be associated with a
heightened risk of thromboembolism. However, the risk associated with mild and moderate …

Scarce data exist regarding the clinical sequelae of COVID-19 and/or the prevalence of
thromboembolic disease in asymptomatic patients. Surely, there is increased prevalence of …

The novel COVID-19-related disorders have become a global health problem since the
pandemic emerged in China. Herein, we present a case of late pulmonary embolism …

SARS-CoV-2 infection is associated with increased risk of thrombosis in severely ill patients
but little is known about the risk in outpatients with mild to moderate disease. Our case …

COVID-19 is the infectious disease caused by a recently discovered SARS-CoV-2.
Following an initial outbreak in December 2019 in Wuhan, China, the virus has spread …

Hypercoagulability state is common in patients with coronavirus disease 2019 (COVID-19),
especially those requiring intensive care. Indeed, anticoagulation therapy is recommended …

Background The venous thromboembolism (VTE) is a frequent condition, which may worsen
the prognosis of hospitalized COVID-19 patients. Nevertheless, the incidence of this …

Background: Hypercoagulation is one of the striking features of COVID-19. Patients
hospitalized with COVID-19 are at high risk for venous thromboembolism. However, it is …

BACKGROUND Emerging reports indicate a high incidence of venous thromboembolism in
patients hospitalised for SARS-CoV-2 pneumonia during the spring 2020 pandemic. The …

Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban
Treatment - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …